Amerise Biosciences Limited (AMERISE) Fair Value & Analysis
Financial Services · IN · Market cap ₹5.4M
Fair value as of: Jul 5, 2026
From 12 valuation models · updated today
Share price +9.5% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹0.5000 – ₹0.9000 · fair‑value band ₹0.3700 – ₹0.6100 · the ₹0.8100 price screens above the ₹0.4900 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Amerise Biosciences Limited (AMERISE) currently trades at ₹0.8100, while our model-based Fair Value estimate is ₹0.4900 — implying the stock looks roughly 39.5% overvalued today. We read business quality at 61/100 (solid quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Trailing-twelve-month revenue stands at ₹3.6M. Revenue declined 57.9% year over year. It earns a return on equity of 0.3%. Fundamentals as of Jul 5, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Amerise Biosciences Limited does not have significant operations. Previously, it was involved in the commodity trading business. The company was formerly known as Amradeep Industries Limited and changed its name to Amerise Biosciences Limited in December 2021. Amerise Biosciences Limited was incorporated in 1984 and is based in Ahmedabad, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Amerise Biosciences Limited reported revenue of ₹0 in FY2026 versus ₹90.1M in FY2022. Reported net income was ₹161K in FY2026, compounding −58.6%/yr from FY2022.
Is AMERISE fairly valued? → Check now
Similar stocks
6 more Shell Companies stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Coca-Cola Company COLA | C$27.96 | C$11.59 | -59% |
| Lionheart III Corp LION | $15.21 | $14.33 | -6% |
| Agriculture & Natural Solutions Acquisition Corporation ANSC | $11.40 | $4.13 | -64% |
| AA Mission Acquisition Corp AAM | $0.0330 | $0.0500 | +52% |
| GP-Act III Acquisition Corp GPAT | $10.90 | $4.30 | -61% |
| Berto Acquisition Corp TACO | $10.40 | $2.73 | -74% |
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is Amerise Biosciences Limited (AMERISE) undervalued?
What is the fair value of AMERISE?
What is the quality score of AMERISE?
What is the revenue of Amerise Biosciences Limited (AMERISE)?
What is the net profit margin of AMERISE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.